Skip to main content
. 2021 Sep 23;22(6):1348. doi: 10.3892/etm.2021.10783

Figure 3.

Figure 3

ST8SIA6-AS1 sponges miR-142-3p in liver cancer. (A) The binding sites of ST8SIA6-AS1 and miR-142-3p were identified via bioinformatics prediction. (B and C) The luciferase reporter assay confirmed the direct binding interaction between miR-142-3p and ST8SIA6-AS1 with the WT binding sites in (B) HepG2 and (C) Hep3B cells. (D) Fold enrichment of ST8SIA6-AS1 expression after RNA pull-down experiment with HepG2 and Hep3B cell extracts in different groups. (E) The expression of miR-142-3p in HepG2 and Hep3B cells with ST8SIA6-AS1 knockdown. (F) Relative expression of miR-142-3p in human liver cancer tissues. (G) The correlation between ST8SIA6-AS1 and miR-142-3p in liver cancer patients was examined using Spearman's correlation analysis. (H) Relative expression of miR-142-3p in human liver cancer cell lines. Values are presented as the mean ± SD and are representative of three individual experiments. **P<0.01, ***P<0.001 as indicated or vs. HL-7702. ns, no significance. ST8SIA6-AS1, ST8 α-N-acetyl-neuraminide α-2,8-sialyltransferase 6 antisense 1; miR, microRNA; WT, wild-type; MUT, mutant; hsa, Homo sapiens; NC, negative control; HCC, hepatocellular carcinoma; Bio, biotin.